West Pharmaceutical Services (NYSE:WST) Issues Q2 2026 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) issued an update on its second quarter 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 2.050-2.120 for the period, compared to the consensus EPS estimate of 2.000. The company issued revenue guidance of $830.0 million-$850.0 million, compared to the consensus revenue estimate of $818.7 million. West Pharmaceutical Services also updated its FY 2026 guidance to 8.400-8.750 EPS.

West Pharmaceutical Services Price Performance

NYSE:WST opened at $309.25 on Friday. The company has a current ratio of 3.02, a quick ratio of 2.34 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $22.29 billion, a P/E ratio of 45.54, a P/E/G ratio of 2.92 and a beta of 1.15. West Pharmaceutical Services has a 12 month low of $199.89 and a 12 month high of $322.34. The business’s 50-day moving average is $252.00 and its 200 day moving average is $262.10.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 EPS for the quarter, topping analysts’ consensus estimates of $1.68 by $0.45. The company had revenue of $844.90 million for the quarter, compared to the consensus estimate of $779.68 million. West Pharmaceutical Services had a return on equity of 17.90% and a net margin of 16.06%.The firm’s revenue for the quarter was up 21.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.45 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, equities research analysts forecast that West Pharmaceutical Services will post 7.91 earnings per share for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 6th. Shareholders of record on Wednesday, April 29th will be paid a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Wednesday, April 29th. West Pharmaceutical Services’s payout ratio is presently 12.96%.

West Pharmaceutical Services announced that its Board of Directors has authorized a stock buyback program on Tuesday, February 17th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical instruments supplier to purchase up to 5.6% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Evercore reduced their price objective on West Pharmaceutical Services from $390.00 to $320.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of West Pharmaceutical Services in a research note on Friday, January 9th. UBS Group reissued a “buy” rating and set a $340.00 price objective on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Jefferies Financial Group reissued a “buy” rating and set a $295.00 price objective on shares of West Pharmaceutical Services in a research note on Tuesday, February 10th. Finally, Zacks Research cut West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 14th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $315.67.

Key Headlines Impacting West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Q1 beat and strong operating performance: West reported Q1 EPS of $2.13 vs. consensus ~$1.68 and revenue of $844.9M (≈+21% YoY). Management cited margin expansion and solid returns. PR Newswire Q1 Release
• Positive Sentiment: Raised guidance: West lifted FY‑2026 EPS to $8.40–$8.75 (above Street) and Q2 EPS to $2.05–$2.12, and increased revenue outlook to $3.3–$3.4B — signaling confidence in demand and pricing. Reuters: Forecast Lift
• Positive Sentiment: Product mix & HVP growth driving upside: Management and coverage note strong demand for higher‑value packaging components (syringes, cartridges, packaging) that are boosting revenues and margins. Analysts raised EPS views on HVP momentum. Zacks: HVP Growth
• Neutral Sentiment: Analyst and market reaction: Multiple outlets summarized the quarterly call and analysts have updated models; slides and the conference call are available for deeper detail — useful for confirming sustainability of growth drivers. MarketBeat: Call/Slides
• Negative Sentiment: Valuation and positioning risk: WST trades at a premium (P/E ~45) and near its 12‑month high, which could limit upside or increase volatility if organic growth or margin expansion slows. Seeking Alpha: Market Reaction

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Aptus Capital Advisors LLC grew its stake in shares of West Pharmaceutical Services by 5.5% during the fourth quarter. Aptus Capital Advisors LLC now owns 905 shares of the medical instruments supplier’s stock valued at $249,000 after buying an additional 47 shares during the last quarter. IFM Investors Pty Ltd grew its stake in shares of West Pharmaceutical Services by 0.4% during the fourth quarter. IFM Investors Pty Ltd now owns 13,730 shares of the medical instruments supplier’s stock valued at $3,778,000 after buying an additional 49 shares during the last quarter. Benjamin Edwards Inc. grew its stake in shares of West Pharmaceutical Services by 1.7% during the second quarter. Benjamin Edwards Inc. now owns 3,021 shares of the medical instruments supplier’s stock valued at $661,000 after buying an additional 50 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of West Pharmaceutical Services by 4.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,207 shares of the medical instruments supplier’s stock valued at $334,000 after buying an additional 53 shares during the last quarter. Finally, Caerus Investment Advisors LLC grew its stake in shares of West Pharmaceutical Services by 6.2% during the fourth quarter. Caerus Investment Advisors LLC now owns 1,035 shares of the medical instruments supplier’s stock valued at $285,000 after buying an additional 60 shares during the last quarter. Institutional investors own 93.90% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.